Work

A phase I study of ATR inhibitor BAY1895344 (elimusertib) plus topotecan (ETCTN 10402): Results of dose escalation.

Year: 2024

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2024.42.16_suppl.3076

Authors: Shannon Stockton, Cathy Shyr, Michael Cecchini, Raid Aljumaily, Thorvardur Ragnar Halfdanarson, Mohamad B. Sonbol, Jennifer Whisenant, S. Percy Ivy, Patricia LoRusso, Satya Das, Steven Gore, Jordan Berlin, Jan Hendrik Beumer, Thatcher Ross Heumann

Institutions: Vanderbilt University, Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center, Yale Cancer Center, Yale University, OU Health Stephenson Cancer Center, University of Oklahoma Health Sciences Center, Mayo Clinic, Mayo Clinic Hospital, Mayo Clinic Comprehensive Cancer Center (Arizona), National Cancer Institute, National Institutes of Health, UPMC Hillman Cancer Center

Language: English

Topic: Cancer therapeutics and mechanisms

Subfield: Molecular Biology

Field: Biochemistry, Genetics and Molecular Biology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W4399737478

Cites:

Cited by: 9

Related to: 10